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Cost–effectiveness analysis of revised WHO 
guidelines for management of childhood 
pneumonia in 74 Countdown countries
Background Treatment of childhood pneumonia is a key priority in 
low–income countries, with substantial resource implications. WHO 
revised their guidelines for the management of childhood pneumonia 
in 2013. We estimated and compared the resource requirements, total 
direct medical cost and cost-effectiveness of childhood pneumonia man-
agement in 74 countries with high burden of child mortality (Count-
down countries) using the 2005 and 2013 revised WHO guidelines.
Methods We constructed a cost model using a bottom up approach to 
estimate the cost of childhood pneumonia management using the 2005 
and 2013 WHO guidelines from a public provider perspective in 74 
Countdown countries. The cost of pneumonia treatment was estimat-
ed, by country, for year 2013, including costs of medicines and service 
delivery at three different management levels. We also assessed coun-
try–specific lives saved and disability adjusted life years (DALYs) avert-
ed due to pneumonia treated in children aged below five years. The 
cost-effectiveness of pneumonia treatment was estimated in terms of 
cost per DALY averted by fully implementing WHO treatment guide-
lines relative to no treatment intervention for pneumonia.
Results Achieving full treatment coverage with the 2005 WHO guide-
lines was estimated to cost US$ 2.9 (1.9–4.2) billion compared to an 
estimated US$ 1.8 (0.8–3.0) billion for the revised 2013 WHO guide-
lines in these countries. Pneumonia management in young children fol-
lowing WHO treatment guidelines could save up to 39.8 million DALYs 
compared to a zero coverage scenario in the year 2013 in the 74 Count-
down countries. The median cost-effectiveness ratio per DALY averted 
in 74 countries was substantially lower for the 2013 guidelines: US$ 
26.6 (interquartile range IQR: 17.7–45.9) vs US$ 38.3 (IQR: US$ 26.2–
86.9) per DALY averted for the 2005 guideline respectively.
Conclusions Child pneumonia management as detailed in standard 
WHO guidelines is a very cost–effective intervention. Implementation 
of the 2013 WHO guidelines is expected to result in a 39.5% reduc-
tion in treatment costs compared to the 2005 guidelines which could 
save up to US$ 1.16 (0.68–1.23) billion in the 74 Countdown coun-
tries, with potential savings greatest in low HIV burden countries which 
can implement effective community case management of pneumonia.
www.jogh.org •  doi: 10.7189/jogh.07.010409	 1	 June 2017  •  Vol. 7 No. 1 •  010409
Globally, pneumonia is a leading cause of mortality and morbidity in young 
children accounting for about 0.935 million deaths in 2013 (15% of un-
der–five mortality) [1] and 120 million episodes worldwide in 2010 [2]. 
Implementation of the World Health Organization (WHO) and United Na-
Electronic supplementary material:  
The online version of this article contains supplementary material.
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tions International Children's Emergency Fund (UNICEF) recommended integrated management of child-
hood illness (IMCI) strategy can potentially reduce 32 to 70% of pneumonia–specific under–five mortal-
ity [3–5]. However, treatment of childhood pneumonia places a large economic burden on families and 
the health care system, especially in resource–constrained countries. Severe acute lower respiratory infec-
tions (ALRI) places a substantial burden on health services worldwide and is a major cause of hospital re-
ferral and admission in young children [6]. The World Health Report (WHR) 2005 estimated that if a com-
prehensive package of child survival interventions was scaled up to 95% coverage in 74 high (child 
mortality) burden countries [7], by 2015 the costs for managing pneumonia would be equivalent to an ad-
ditional US$ 1.48 per capita (2004 US$, inflated to 1.83 in 2013 US$) from public provider’s perspective.
In 2013, WHO revised the guidelines for the management of childhood pneumonia [8–10]. The key 
change in the 2013 guidelines is that Human Immunodeficiency Virus (HIV)–uninfected children (aged 
1 month – 4 years) with lower chest wall in–drawing (with or without tachypnoea) are classified as hav-
ing pneumonia and recommended management at first level facilities (as out–patients) with oral dispers-
ible amoxicillin instead of co–trimoxazole and no longer need to be treated at a hospital (see Box S1 in 
Online Supplementary Document). They also recommend that HIV–infected children with lower chest 
wall in–drawing should be considered as having severe pneumonia and referred for hospital admission 
and treatment with ampicillin plus gentamicin IM or IV. Several clinical trials in the past few years have 
suggested that the treatment protocols in the revised (2013) guidelines are as effective as those in the pre-
vious (2005) guidelines in terms of measured clinically–defined rates of treatment failure and from this 
it has been inferred that they should have at least a similar impact on mortality [11–18].
However, we are not aware of any studies to date that report country level cost estimates for the 2013 
WHO treatment guidelines. Existing studies that report cost of treatment of pneumonia mainly focus on 
the cost of illness per episode for each individual patient and demonstrate a considerable degree of meth-
odological heterogeneity [19]. This greatly limits the extent to which valid national and international eco-
nomic analyses can be carried out to inform international child health policy on pneumonia.
We aimed to estimate the cost of pediatric pneumonia management (from a public provider perspective) 
using the 2013 WHO guidelines, estimate cost-effectiveness (and cost savings) compared to use of the 
2005 guidelines and estimate the country–specific annual investment required for childhood pneumonia 
management in the 74 Countdown countries prioritised by the “Countdown to 2015” initiative. These 
countries account for 97% of the maternal and child deaths worldwide [7].
METHODS
Study design
We constructed a cost model using a bottom up approach to estimate the total cost of pneumonia man-
agement using the 2005 and 2013 WHO guidelines from a public provider perspective in the 74 Count-
down countries. In the absence of information on the clients’ preferred use of providers and challenges 
related to making predictions on private/public split, we applied public provider cost profiles to the anal-
ysis. We also used the WHO recommended template [20] to assess country–specific lives saved and dis-
ability adjusted life years (DALYs) averted in pneumonia cases (in children aged below five years receiv-
ing treatment in the 74 Countdown countries (comparing universal treatment coverage of cases to no 
treatment). DALYs for a disease were calculated as the sum of the Years of Life Lost (YLL) due to prema-
ture mortality in the population and the Years Lost due to Disability (YLD) for people living with the dis-
ease condition and its consequences. These 74 priority countries account for a population of 5.1 billion, 
with 520 million children aged below five years in 2013, and 97% of global pneumonia deaths [21].
We estimated the total cost of pneumonia treatment at a country level in the year 2013 assuming univer-
sal coverage (100%), including the total cost for medicine and service delivery at three different levels – 
community, first level health facility, and first referral hospital level. The total medicine cost and service 
delivery cost in each country were calculated for each delivery level based on the coverage and popula-
tion in need. We used the standard treatment protocol recommended by the WHO including recom-
mended dosage for antibiotics, supportive therapy and duration of treatment [8]. We estimated the cost 
of management of pneumonia in HIV–infected and uninfected children following the 2005 and 2013 
WHO guidelines. In the absence of empirical data, we assumed that the proportion of pneumonia signs 
(ie, fast breathing, lower chest wall in–drawing and danger signs) are the same in HIV–infected and un-
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Cost effectiveness of revised WHO guidelines
infected children with pneumonia – 85% of children with pneumonia have fast breathing, 13% have chest 
wall in–drawing and about 2% have danger signs – based on the results of studies carried out at the com-
munity level [15,22,23].
Cost model inputs
The 74 countries were categorised into four groups based on HIV prevalence and the presence or absence 
of an implemented pneumonia community case management (CCM) policy. Community case manage-
ment refers to an integrated strategy to achieve high treatment coverage and delivering high–quality care 
to sick children in the community.by community health workers. A country was defined as “high HIV 
prevalence country” when the adult prevalence (15–49 years) was above 1% in 2012. The proportion of 
the adult population infected by HIV was obtained from UNAIDS (2012) [24]. The standard treatment 
procedure in children who are HIV positive and negative are different as per the WHO guidelines. Infor-
mation on policy and implementation of CCM were obtained from the Countdown Reports for 2014 [25] 
and 2012 [7]; these influenced assumptions regarding the proportion of the rural population seeking 
treatment at first level facility or community level.
The estimated country–specific population in need for each level of intervention was calculated using 
three parameters: population size, pneumonia incidence and urban/rural distribution of the population. 
The exposed population in need was calculated using the country level population of children aged be-
low five years from the UN World Population Prospects [21], and the most recent published country–
specific estimates of incidence of pneumonia among children below five years [26]. The population living 
in rural areas was estimated using the UN World Urbanisation Prospects (2011) [27], and we estimated 
the population in need at the community and facility level for urban and rural areas separately. The num-
ber of pneumonia cases in HIV–infected children was obtained from recently published estimates [26].
We assumed universal coverage of pneumonia treatment with 100% children affected by pneumonia be-
ing treated either at community, first level health facility or first referral hospital level. Community level 
treatment implies a community health worker (CHW) treating the child at home. In countries with im-
plementation of a CCM policy, we assumed that half of the rural population would be treated by CHWs 
and the remaining half would be treated at a health facility [15,19]. We assumed that the urban popula-
tion would be treated at first level health facility and first referral hospital level. We conducted sensitivity 
analyses to examine the change in the overall cost of pneumonia treatment by varying the coverage of the 
rural population by CHWs. We considered two different types of direct medical costs – cost of medicines 
and costs related to service delivery. All costs are presented in US dollars (2013), and are estimated by 
level of intervention and country. We used median supplier prices from Management Sciences for Health 
(MSH) International Price Indicator (2012) [28], UNICEF supply division data, and UNICEF report for 
cost of medicines [29] for the list of drugs based on the previous and revised WHO guidelines. Costs were 
estimated for an average child weighing 10 kg (around one–year–old) due to lack of age disaggregated 
population data.
Country–specific service delivery costs (ie, costs for one inpatient day and one outpatient visit) were ob-
tained from the World Health Organization Choosing Interventions that are Cost–Effective project (WHO–
CHOICE) estimates [30] (which include operational costs such as health worker consultation time, elec-
tricity and maintenance of health facility buildings). We applied outpatient unit costs from WHO–CHOICE 
for service delivery at the first level facility and inpatient unit costs for service delivery at the first referral 
level hospital. For the community level service delivery, we used the salary received by CHWs in the pub-
lished literature [31], which was supplemented by consultation with experts from WHO. The number of 
CHWs needed per country was obtained by assuming one CHW per 1000 rural population [31].
Effectiveness of pneumonia treatment
The effectiveness of pneumonia treatment was measured in terms of country–specific disability adjusted 
life years (DALYs) averted by implementing WHO treatment guidelines relative to no treatment interven-
tion for pneumonia, ie, implementation of 2005 guidelines vs no treatment and implementation of 2013 
guidelines vs no treatment. Country–specific DALYs were computed using the WHO DALY Calculation 
Template [20,32]. We obtained country–specific population data by gender for children aged 0–4 years 
and the life expectancy at birth for both the sexes from the World Population Prospect (2013) [21], and 
used pneumonia specific incidence and mortality estimates published recently [1,2,26]. Deaths averted 
by pneumonia treatment were calculated based on the reported estimates of 70% child mortality reduc-
www.jogh.org •  doi: 10.7189/jogh.07.010409	 3	 June 2017  •  Vol. 7 No. 1 •  010409
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tion from universal coverage of community management of childhood pneumonia [33]. We assumed that 
the 2005 and 2013 guidelines have the same treatment effectiveness and that community management 
of fast breathing pneumonia and health facility management of fast breathing and lower chest in–draw-
ing pneumonia with oral amoxicillin (based on the clinical trials [11–18]) have similar effectiveness in 
terms of mortality reduction. We assumed that the peak incidence of childhood pneumonia was at 1.5 
months and that median age at death was 8.9 months based on unpublished data from Kilifi, Kenya, (Jay 
Berkley, personal communication); these were also supported by published literature and expert opinion 
[34,35]. Disability weight is a weighting factor that reflects the severity of the disease on a scale from 0 
(perfect health) to 1 (dead). For our analysis, we applied a standard disability weight of 0.21 for infec-
tious disease (acute episode, severe) [36].
Cost-effectiveness is measured in terms of cost per DALY averted in each country. The thresholds for con-
sidering an intervention to be cost–effective were set following the recommendations of the Commission 
on Macroeconomics and Health [37]. Interventions that cost less than three times the average gross do-
mestic product (GDP) per capita income per DALY averted were considered to be cost–effective and an 
intervention whose cost per DALY averted was less than the average per capita income for a given coun-
try was considered to be highly cost–effective.
Sensitivity analysis
We simulated the cost estimates using several scenarios by varying unit cost, length of stay in hospital, 
level of coverage and population in need (Box S2 in Online Supplementary Document). We extracted 
an actual cost data scenario derived from a systematic review of the published literatures based on 34 cost 
studies, and incorporated these data into our model to compare the results with the standard prices mod-
el [19]. We also conducted sensitivity analyses assuming 100% rural coverage for CCM implementation, 
36% of mortality reduction, 1 CHW per 5000 rural population and 9%–30% of effective access rate to 
health care in rural areas [38]. Additionally, we performed several analyses to examine a range of total 
costs and cost savings in each country to assess whether / within what parameter settings the interven-
tion remained cost–effective.
We conducted the analyses using Microsoft Excel 2010 (Microsoft Corp., Redmond, WA, USA).
RESULTS
Total cost and cost savings
The total direct medical cost of management of all–cause childhood pneumonia in the 74 Countdown 
countries in 2013 using the 2005 IMCI guidelines was estimated to be about US$ 2.94 billion. However, 
implementation of the 2013 IMCI guidelines would cost approximately US$ 1.78 billion (Table 1). Thus, 
a total of US$ 1.16 billion could potentially be saved by implementing the 2013 guidelines in these coun-
tries. About 82% of these cost savings could be achieved in countries in the WHO South–East Asia, Af-
rica and Western Pacific regions (Figure 1), which account for the majority of cases and deaths due to 
childhood pneumonia. These findings can be further broken down into cost at the three delivery levels 
Figure 1. Percentage of Total Cost Savings by WHO Regions (number of countries in each region), total estimated 
cost savings in 2013: US$ 1.16 billion. Total cost savings (Unit: Billion) SEAR: 0.53; WPR: 0.24; AFR: 0.18; EMR: 
0.099; AMR: 0.094; EUR: 0.014.
Zhang et al.
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when following the 2013 guidelines, but this was outweighed by the substantial reduction in costs at the 
hospital level (Table 2).
Our estimates of country–specific cost for the management of childhood pneumonia demonstrate that 
ten countries (Bangladesh, China, India, Mexico, Pakistan, Indonesia, Philippines, Brazil, Nigeria and 
South Africa) account for about three quarters of the total cost in the 74 Countdown countries (Table 3). 
Potentially up to US$ 933 million could be saved in these ten countries alone by fully implementing the 
2013 guidelines which corresponds to about 80% of the total cost savings in the 74 countries.
Cost savings by HIV prevalence
In low HIV prevalence countries, treatment costs for HIV–infected patients accounted for less than one 
percent of the total cost of pneumonia management. Countries with high HIV prevalence require a larg-
er share (between 0.82% and 65.20%) of the total direct medical cost investment to manage pneumonia 
in young HIV–infected children. Following implementation of the 2013 guidelines, countries implement-
ing CCM can achieve substantial cost savings of US$ 1.00 billion collectively compared to savings of only 
$0.16 billion in those not implementing CCM, particularly in low HIV burden settings (Table S1 in On-
line Supplementary Document).
Total cost per capita
Globally, the total cost per capita for direct medical pneumonia costs of treatment (based on an assumed 
100% treatment coverage) ranged from US$ 0.04 (in Brazil on one extreme) to US$ 2.13 (in Equatorial 
Guinea at the other extreme). Similarly, total health care expenditure per capita using the 2013 guidelines 
ranged from 0.0035% (Brazil on the lower end) to 12.47% (Somalia on the higher end) (Table 2). The 
median total cost per capita for the 2013 guidelines among 74 countries was US$ 0.38 (IQR: US$ 0.24–
0.47), which represented 0.52% (IQR: 0.15%–1.14%) of total health care expenditure per capita. This is 
lower than that for the 2005 guideline – US$ 0.54 (IQR: US$ 0.40–0.75). In seven countries (Eritrea, Ni-
ger, Somalia, Burundi, Central African Republic, Madagascar, and Ethiopia), the estimated total cost of 
pneumonia treatment per capita exceeds 2% of the total health care expenditure per capita following the 
2013 guidelines.
Cost–effectiveness of 2005 and 2013 guidelines
Assuming that the two sets of guidelines are equally effective (see above) then adopting the 2013 guide-
lines should help many countries achieve a more cost–effective pneumonia management strategy and 
should result in substantial savings per DALY averted, compared to the 2005 guidelines. Following the pa-
rameters described above and 100% treatment coverage, our model estimates that up to 39.8 million DALYs 
could be averted in the 74 countries. We also estimate that the total Years of Life Saved would be 38.8 mil-
lion and total deaths averted would be about 0.63 million. This yields a median cost–effectiveness ratio of 
$38.3 (IQR: US$ 26.2–86.9) and US$ 26.6 (IQR: 17.7–45.9) per DALY averted using the 2005 and 2013 
guidelines respectively. The median cost per DALY averted for 74 countries was US$ 11.5 (IQR US$ 7.2–
30.0). We estimated that nine countries with highest cost per DALYS averted – China, Mexico, Peru, Bra-
zil, Gabon, Botswana, Equatorial Guinea, Azerbaijan and South Africa – could save between US$ 95.6 and 
US$ 284.8 per DALY averted if the 2013 guidelines were fully implemented (Table 4).
Sensitivity analysis results
We conducted sensitivity analyses by varying the unit price of medicine (Tables S2–S4 in Online Supple-
mentary Document), CHW/rural population ratio and CHW coverage (Tables S5–S7 in Online Supple-
mentary Document), effective access to health care in rural areas (Tables S8–S10 in Online Supplemen-
Table 1. Total cost of management of childhood pneumonia in 74 Countdown countries in 2013
Delivery level ToTal cosT for pneumonia TreaTmenT in 2013 (Billions, in 2013 us$)
2005 Guidelines [10] 2013 Guidelines [8] 2013 Guidelines/2005 
Guidelines %Total Cost % Total Total cost % Total
Community 1.25 42.4 1.25 70.4 100.3
First level facility 0.18 6.1 0.23 12.8 126.0
Hospital 1.51 51.4 0.30 16.9 19.9
Total cost 2.94 100 1.78 100.0 60.5
Cost effectiveness of revised WHO guidelines
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Table 2. Total treatment cost by country for each level of service delivery*
counTry ToTal TreaTmenT cosT By Delivery level for 2005 
GuiDelines [10] (ThousanDs, 2013 us$)
ToTal TreaTmenT cosT By Delivery level for 2013 
GuiDeline [8] (ThousanDs, 2013 us$)
ToTal TreaTmenT cosT raTio: 2013 GuiDelines/2005 
GuiDelines (%)
Community First level 
facility
Primary 
hospital
Community First level 
facility
Primary 
hospital
Commu-
nity
First 
level 
facility
Primary 
hospital
Total
Afghanistan 11 401.08 10 460.50 12 278.82 11 516.61 13 283.25 1794.78 101.01 126.98 14.62 77.90
Angola – 1114.05 23 277.54 – 1401.03 5088.23 – 125.76 21.86 26.60
Azerbaijan 2120.28 1286.70 6289.06 2125.15 1561.02 1274.37 100.23 121.32 20.26 51.16
Bangladesh 54 523.08 2917.34 27 298.93 54 727.21 4065.44 4227.04 100.37 139.35 15.48 74.37
Benin 2764.68 128.71 2029.47 2775.73 190.67 358.01 100.40 148.13 17.64 67.53
Bolivia (Plurinational 
State of)
– 242.95 1709.18 – 297.57 316.86 – 122.48 18.54 31.47
Botswana – 44.29 2430.51 – 57.19 766.37 – 129.11 31.53 33.28
Brazil – 2295.24 26 878.76 – 2888.23 5004.98 – 125.84 18.62 27.06
Burkina Faso 6066.40 964.40 5864.39 6116.28 1301.36 981.56 100.82 134.94 16.74 65.13
Burundi 4399.71 709.60 1123.25 4414.11 923.06 199.84 100.33 130.08 17.79 88.84
Cambodia – 455.79 1666.49 – 559.87 288.41 – 122.83 17.31 39.97
Cameroon 5182.60 258.02 5652.74 5202.16 381.90 1298.54 100.38 148.01 22.97 62.04
Central African 
Republic
– 6789.37 1118.01 – 7794.68 267.34 – 114.81 23.91 101.96
Chad – 720.47 4500.48 – 926.15 941.21 – 128.55 20.91 35.77
China 332 126.14 4231.84 250 139.39 332 389.24 6056.05 48 630.31 100.08 143.11 19.44 66.00
Comoros – 448.69 213.26 – 522.36 33.25 – 116.42 15.59 83.94
Congo 786.08 127.92 2897.28 789.56 169.37 699.90 100.44 132.40 24.16 43.52
Congo, Democratic 
Republic
21 593.58 1991.78 11 753.02 21 710.58 2730.74 1876.43 100.54 137.10 15.97 74.47
Côte d'Ivoire – 2526.81 7 952.09 – 3 043.90 1 740.60 – 120.46 21.89 45.66
Djibouti – 40.93 266.28 – 51.46 53.53 – 125.74 20.10 34.18
Egypt – 1466.52 13,334.03 – 1809.30 2479.44 – 123.37 18.59 28.98
Equatorial Guinea – 14.07 5042.05 – 19.36 1591.47 – 137.59 31.56 31.86
Eritrea 2421.25 85.68 2007.63 2429.03 122.15 380.68 100.32 142.57 18.96 64.94
Ethiopia 37 952.87 919.68 10 635.81 38 069.35 1359.98 1948.09 100.31 147.87 18.32 83.58
Gabon – 49.79 2770.42 – 63.20 688.00 – 126.95 24.83 26.64
Gambia 384.33 87.02 388.63 386.11 111.45 70.00 100.46 128.08 18.01 66.00
Ghana 6053.11 350.63 4385.54 6067.41 474.13 866.40 100.24 135.22 19.76 68.66
Guatemala 3774.98 234.93 1857.80 3786.51 324.04 284.08 100.31 137.93 15.29 74.90
Guinea 3689.35 699.79 2357.00 3707.74 901.87 419.99 100.50 128.88 17.82 74.56
Guinea–Bissau – 68.07 377.07 – 87.36 88.04 – 128.34 23.35 39.40
Haiti – 517.71 1298.83 – 626.76 238.43 – 121.06 18.36 47.63
India 418 239.33 16 406.87 591 463.73 419 709.33 23 682.25 112 428.79 100.35 144.34 19.01 54.17
Indonesia 59 799.61 4929.74 35 865.47 59 913.35 6346.30 6344.94 100.19 128.73 17.69 72.18
Iraq – 9823.46 20 550.40 – 11 456.60 4154.23 – 116.62 20.21 51.40
Kenya – 5337.83 7865.87 – 6275.86 1904.43 – 117.57 24.21 61.95
Korea, Democratic 
People's Republic
4795.55 145.40 4851.59 4802.07 204.49 912.74 100.14 140.64 18.81 60.45
Kyrgyzstan 1743.10 99.15 1107.97 1748.98 136.66 183.49 100.34 137.83 16.56 70.13
Lao People's  
Democratic Republic
2164.27 117.75 1909.82 2173.38 167.33 332.71 100.42 142.10 17.42 63.78
Lesotho – 50.08 472.47 – 63.35 218.85 – 126.49 46.32 54.00
Liberia 1561.98 261.60 660.00 1566.95 332.13 101.53 100.32 126.96 15.38 80.55
Madagascar 7520.89 944.39 4473.18 7559.02 1253.21 687.17 100.51 132.70 15.36 73.42
Malawi 6705.06 732.96 1979.92 6724.64 934.94 669.24 100.29 127.56 33.80 88.44
Mali 4848.14 1647.53 4249.70 4878.90 2094.76 722.41 100.63 127.15 17.00 71.62
Mauritania 1107.71 478.22 1172.87 1113.42 597.55 207.50 100.51 124.95 17.69 69.54
Mexico 12 994.34 1491.12 77 172.09 13 012.59 1921.17 15 409.53 100.14 128.84 19.97 33.11
Morocco – 4556.94 6606.32 – 5309.92 1237.23 – 116.52 18.73 58.65
Mozambique 8652.85 5520.45 6414.29 8700.73 6780.13 1999.95 100.55 122.82 31.18 84.91
Myanmar 17 424.61 762.94 7406.96 17 467.28 1041.27 1272.04 100.24 136.48 17.17 77.28
Nepal 11 210.34 678.15 3103.69 11 239.79 907.35 477.82 100.26 133.80 15.40 84.21
Niger 7138.68 2330.37 4913.61 7193.46 3 030.11 741.45 100.77 130.03 15.09 76.24
Nigeria 42 534.99 26 108.57 59 338.83 42 732.87 31 949.59 13 508.53 100.47 122.37 22.77 68.91
Zhang et al.
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tary Document) and the proportion of pneumonia signs in HIV– infected children with pneumonia 
(Tables S11–S13 in Online Supplementary Document, higher cost from published studies but less ef-
fective scenario (Tables S14–S18 in Online Supplementary Document). This way we designed 6 likely 
scenarios (See Box S2 in Online Supplementary Document). These analyses demonstrated that the to-
tal direct medical cost of pneumonia treatment was US$ 1.9–4.2 billion based on universal coverage of 
the 2005 WHO guidelines and US$ 0.8–3.0 billion following the 2013 guidelines. The estimated cost 
savings (from a public provider perspective) by implementing the 2013 guidelines ranged between US$ 
0.7 and US$ 1.2 billion, eg, in the effective access scenario, with a 9%–30% effective access rate applied 
to rural population, total cost saving was US$ 0.78 billion (Table S8 in Online Supplementary Docu-
ment). The median cost–effectiveness ratio ranged from US$ 12.8 (IQR: 8.8–25.6) to US$ 56.0 (34.7–
120.2) per DALY averted. Both 2005 and 2013 guidelines for the pneumonia treatment interventions re-
mained highly cost–effective in all scenarios.
Discussion
Treatment of childhood pneumonia poses a substantial economic burden in resource limited low–income 
countries. Our study is the first to estimate the direct medical cost to the public sector of pneumonia 
management at community, first level facility, and first referral hospital levels using the 2005 and 2013 
WHO guidelines. In this analysis we have studied “pneumonia” as defined by WHO case management 
and realize that this case definition encompasses other acute lower respiratory conditions such as bron-
chioliitis. We have demonstrated that implementation of the 2013 IMCI guidelines for the treatment of 
childhood pneumonia is expected to result in substantial cost savings (up to 39.5% of the budget for 
pneumonia treatment) and saved 38.8 millions years of life globally (Table S19 in Online Supplemen-
tary Document). More than 80% of the estimated global savings would be made by implementing the 
2013 guidelines in ten high burden countries alone (Table 2). Although implementation of these guide-
Table 2. Continued
counTry ToTal TreaTmenT cosT By Delivery level for 2005 
GuiDelines [10] (ThousanDs, 2013 us$)
ToTal TreaTmenT cosT By Delivery level for 2013 
GuiDeline [8] (ThousanDs, 2013 us$)
ToTal TreaTmenT cosT raTio: 2013 GuiDelines/2005 
GuiDelines (%)
Community First level 
facility
Primary 
hospital
Community First level 
facility
Primary 
hospital
Commu-
nity
First 
level 
facility
Primary 
hospital
Total
Pakistan 56 508.00 16 699.70 46 987.80 56 741.27 21 059.19 7879.04 100.41 126.11 16.77 71.28
Papua New Guinea 3114.48 188.58 1986.34 3124.71 256.22 370.36 100.33 135.87 18.65 70.92
Peru 3352.26 124.13 9306.02 3356.20 181.53 1840.11 100.12 146.24 19.77 42.07
Philippines 24 463.96 3722.85 34 784.32 24 547.02 4779.18 6335.22 100.34 128.37 18.21 56.63
Rwanda 4627.50 308.74 1178.31 4638.29 405.88 224.79 100.23 131.46 19.08 86.17
Sao Tome and 
Principe
– 30.83 33.66 – 35.97 6.74 – 116.68 20.02 66.23
Senegal 3948.39 488.16 3059.40 3962.94 635.97 536.93 100.37 130.28 17.55 68.51
Sierra Leone 1801.09 248.21 1131.77 1810.32 327.56 189.91 100.51 131.97 16.78 73.18
Solomon Islands – 78.99 126.27 – 92.97 22.40 – 117.69 17.74 56.20
Somalia 3185.18 1113.81 2841.88 3211.74 1431.19 410.91 100.83 128.50 14.46 70.77
South Africa – 1275.60 49 053.75 – 1590.69 17 881.83 – 124.70 36.45 38.69
Sudan – 11 281.13 22 475.25 – 13 405.65 3844.41 – 118.83 17.11 51.10
Swaziland – 60.05 520.30 – 70.48 252.13 – 117.35 48.46 55.59
Tajikistan 2932.36 774.56 1777.77 2944.10 986.64 291.31 100.40 127.38 16.39 76.98
Tanzania, United 
Republic of
– 8832.22 7093.35 – 10 288.06 1676.30 – 116.48 23.63 75.13
Togo 2054.78 285.33 1198.07 2063.27 368.76 260.12 100.41 129.24 21.71 76.09
Turkmenistan 1305.42 85.85 2913.80 1308.94 115.77 566.89 100.27 134.85 19.46 46.26
Uganda 15 426.85 943.94 6083.92 15 480.64 1280.18 1522.94 100.35 135.62 25.03 81.43
Uzbekistan 8969.37 862.48 6421.00 8994.75 1121.98 1147.19 100.28 130.09 17.87 69.30
Viet Nam – 4275.11 14 077.75 – 5150.35 2476.74 – 120.47 17.59 41.56
Yemen 8042.85 2660.84 11 772.38 8094.02 3398.63 2058.14 100.64 127.73 17.48 60.29
Zambia 4299.30 574.52 3296.80 4309.87 721.09 1172.36 100.25 125.51 35.56 75.92
Zimbabwe – 643.02 2062.99 – 765.63 832.50 – 119.07 40.35 59.06
Total 1 247 712.75 180 231.49 1 511 555.44 1 251 337.59 227 059.41 300 210.04 100.42 125.98 19.86 60.51
*Total treatment cost ratio of Revised Guidelines vs Old guideline by treatment settings.
Cost effectiveness of revised WHO guidelines
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Table 3. Total cost of management of childhood pneumonia by HIV status
counTry 2005 GuiDelines [10] (ThousanDs, 2013 us$) 2013 GuiDelines [8] (ThousanDs, 2013 us$) ToTal cosT 
savinGs  
(ThousanDs, 
2013 us$)
2013 GuiDelines
HIV+ HIV– Total HIV+ HIV– Total Total 
cost per 
capita
Proportion of 
national health 
care expenditure 
per Capita (%)
Afghanistan 4.78 34 135.63 34 140.41 4.95 26 589.69 26 594.64 7545.77 0.87 1.56
Angola 588.79 23 802.80 24 391.59 808.42 5767.72 6576.13 17815.46 0.30 0.16
Azerbaijan 39.30 9656.73 9696.03 53.31 4907.24 4960.54 4735.49 0.53 0.15
Bangladesh 3.03 84 736.32 84 739.35 3.30 63 016.38 63 019.68 21 719.66 0.40 1.52
Benin 43.96 4878.91 4922.87 48.47 3275.94 3324.41 1598.46 0.32 0.88
Bolivia (Plurina-
tional State of)
4.06 1948.07 1952.13 5.10 577.56 582.66 1369.47 0.06 0.05
Botswana 270.49 2204.32 2474.81 388.96 480.84 869.80 1605.01 0.41 0.09
Brazil 15.10 29 158.90 29 174.00 19.46 7847.54 7867.01 21 306.99 0.04  0.0035
Burkina Faso 132.04 12 763.14 12 895.19 140.12 8259.09 8399.21 4495.98 0.50 1.33
Burundi 75.95 6156.61 6232.56 76.33 5460.68 5537.02 695.55 0.54 2.33
Cambodia 24.87 2097.41 2122.28 27.60 754.28 781.88 1340.40 0.06 0.11
Cameroon 355.52 10 737.84 11 093.36 416.34 6466.27 6882.61 4210.75 0.31 0.45
Central African 
Republic
538.84 7368.55 7907.39 544.55 7521.47 8066.02 –158.64 1.75 9.55
Chad 289.80 4931.14 5220.94 318.28 1563.37 1881.65 3339.29 0.15 0.41
China 83.52 586 413.86 586 497.37 116.07 386 959.53 387 075.60 199 421.77 0.28 0.10
Comoros 0.25 661.70 661.95 0.26 487.15 487.41 174.54 0.76 1.78
Congo 140.61 3670.67 3811.28 185.79 1473.04 1658.82 2152.46 0.37 0.43
Congo, Democrat-
ic Republic
429.87 34 908.51 35 338.38 428.49 25 889.25 26 317.74 9020.64 0.39 1.98
Côte d'Ivoire 565.27 9913.63 10 478.90 637.47 4180.08 4817.55 5661.34 0.24 0.30
Djibouti 10.07 297.13 307.20 11.72 94.00 105.72 201.48 0.12 0.11
Egypt 1.05 14 799.49 14 800.54 1.35 4072.57 4073.92 10 726.63 0.05 0.04
Equatorial Guinea 514.83 4541.29 5056.12 776.24 935.46 1711.70 3344.42 2.13 0.17
Eritrea 17.15 4497.40 4514.55 21.54 2910.33 2931.87 1582.68 0.46 3.33
Ethiopia 552.14 48 956.23 49 508.37 567.44 40 809.98 41 377.42 8130.95 0.44 2.65
Gabon 127.20 2693.01 2820.21 185.24 588.53 773.77 2046.44 0.45 0.13
Gambia 13.10 846.88 859.98 14.09 553.47 567.55 292.43 0.31 1.12
Ghana 118.24 10 671.04 10 789.28 140.10 7267.84 7407.95 3381.33 0.29 0.38
Guatemala 16.60 5851.12 5867.72 17.41 4377.21 4394.63 1473.09 0.28 0.13
Guinea 99.32 6646.82 6746.14 103.90 4925.69 5029.59 1716.55 0.43 1.44
Guinea–Bissau 40.40 404.74 445.14 42.93 133.95 176.88 268.26 0.10 0.28
Haiti 54.97 1761.58 1816.55 58.94 808.36 867.31 949.24 0.08 0.15
India 1669.57 1 024 440.35 1 026 109.93 2193.12 553 627.25 555 820.37 470 289.56 0.44 0.75
Indonesia 125.39 100 469.43 100 594.82 149.35 72 455.25 72 604.59 27 990.23 0.29 0.31
Iraq 310.48 30 063.38 30 373.86 387.99 13 745.27 14 133.26 16 240.60 0.46 0.14
Kenya 1064.89 12 138.81 13 203.70 1146.41 7074.75 8221.16 4982.54 0.18 0.51
Korea, Democratic 
People's Republic
0.21 9792.33 9792.54 0.27 5919.03 5919.30 3873.24 0.24 0.63
Kyrgyzstan 0.43 2949.80 2950.22 0.49 2068.64 2069.13 881.09 0.37 0.52
Lao People's 
Democratic Republic
8.92 4182.93 4191.84 10.47 2662.95 2673.42 1518.42 0.39 1.07
Lesotho 168.05 354.51 522.56 190.83 101.93 292.76 229.79 0.14 0.10
Liberia 17.86 2465.72 2483.58 17.99 1982.63 2000.62 482.96 0.32 0.59
Madagascar 54.14 12 884.32 12 938.46 56.38 9443.03 9499.41 3439.05 0.41 2.18
Malawi 543.94 8873.99 9417.94 556.83 7771.98 8328.82 1089.12 0.51 1.65
Mali 108.31 10 637.06 10 745.37 115.13 7580.94 7696.07 3049.30 0.50 1.13
Mauritania 18.69 2740.12 2758.81 20.91 1897.56 1918.47 840.35 0.49 0.85
Mexico 44.11 91 613.44 91 657.55 63.93 30 279.36 30 343.29 61 314.27 0.25 0.04
Morocco 6.27 11 156.99 11 163.26 7.55 5847.48 5855.04 5308.22 0.20 0.11
Mozambique 1774.32 18 813.27 20 587.58 1841.68 15 639.12 17 480.80 3106.78 0.68 1.92
Myanmar 67.27 25 527.24 25 594.51 76.30 19 704.29 19 780.59 5813.92 0.37 1.65
Nepal 15.35 14 976.83 14 992.18 16.34 12 608.62 12 624.96 2367.23 0.45 1.38
Niger 80.04 14 302.62 14 382.67 81.83 10 883.19 10 965.02 3417.64 0.61 3.06
Nigeria 4233.83 123 748.56 127 982.39 4875.27 83 315.73 88 190.99 39 791.39 0.51 0.64
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counTry 2005 GuiDelines [10] (ThousanDs, 2013 us$) 2013 GuiDelines [8] (ThousanDs, 2013 us$) ToTal cosT 
savinGs  
(ThousanDs, 
2013 us$)
2013 GuiDelines
HIV+ HIV– Total HIV+ HIV– Total Total 
cost per 
capita
Proportion of 
national health 
care expenditure 
per Capita (%)
Pakistan 21.97 120 173.52 120 195.50 24.95 85 654.55 85 679.50 34 516.00 0.47 1.58
Papua New Guinea 20.99 5268.41 5289.40 25.47 3725.83 3751.30 1538.11 0.51 0.65
Peru 19.10 12763.31 12 782.41 26.85 5350.99 5377.84 7404.57 0.18 0.06
Philippines 3.61 62 967.52 62 971.13 4.54 35 656.88 35 661.42 27 309.71 0.36 0.38
Rwanda 62.14 6052.42 6114.56 65.85 5203.11 5268.96 845.59 0.45 0.71
Sao Tome and 
Principe
1.68 62.80 64.49 1.89 40.91 42.80 21.69 0.22 0.19
Senegal 37.10 7458.85 7495.95 42.18 5093.66 5135.84 2360.11 0.36 0.54
Sierra Leone 41.06 3140.00 3181.06 42.06 2285.72 2327.79 853.27 0.38 0.56
Solomon Islands 0.83 204.44 205.27 0.95 102.53 103.48 101.79 0.21 0.15
Somalia 47.85 7093.02 7140.86 47.93 5005.91 5053.84 2087.03 0.48 12.47
South Africa 7868.39 42 460.96 50 329.35 11230.10 9556.77 20 786.88 29 542.47 0.37 0.05
Sudan 126.39 33 629.99 33 756.38 142.23 17 114.97 17 257.20 16 499.17 0.45 0.44
Swaziland 169.06 411.29 580.35 219.61 123.37 342.98 237.37 0.26 0.10
Tajikistan 5.36 5479.34 5484.70 5.92 4216.14 4222.05 1262.65 0.51 0.95
Tanzania, United 
Republic of
1243.91 14 681.66 15 925.57 1287.95 10 703.65 11 991.59 3933.98 0.24 0.65
Togo 105.00 3433.18 3538.18 110.67 2581.48 2692.15 846.03 0.39 0.88
Turkmenistan 4.00 4301.07 4305.08 5.50 1986.10 1991.60 2313.48 0.38 0.29
Uganda 788.10 21 666.61 22 454.70 816.27 17 467.48 18 283.75 4170.95 0.49 1.15
Uzbekistan 26.54 16 226.31 16 552.84 31.81 11232.11 11 263.92 4988.92 0.39 0.44
Viet Nam 74.25 18 278.60 18 352.85 86.23 6906.74 6992.97 11 359.88 0.08 0.09
Yemen 14.65 22 461.41 22 476.07 17.31 13 533.47 13 550.78 8925.28 0.56 0.63
Zambia 690.95 7479.67 8170.62 797.46 5405.86 6203.32 1967.29 0.43 0.49
Zimbabwe 709.98 1996.04 2706.02 760.05 865.22 1625.27 1080.74 0.11 0.29
Total 27 566.10 2 911 933.58 2 939 499.68 33767.00 1 743 376.97 1 777 143.97 1 162 355.70
Table 3. Continued
Table 4. Total DALYs averted and cost–effectiveness of implementing 2013 guidelines
counTry ToTal Daly averTeD  
(ThousanDs)
cosT per Daly averTeD (2013 us$) percenTaGe of cosT per Daly 
averTeD in GDp per capiTa (%)
2005  
Guidelines [10]
2013  
Guidelines [8]
2005 
Guidelines
2013 
Guidelines
Afghanistan 875.44 39.00 30.38 6.29 4.90
Angola 971.25 25.11 6.68 0.46 0.12
Azerbaijan 45.64 212.44 108.68 2.87 1.47
Bangladesh 910.09 93.11 69.25 12.46 9.27
Benin 191.87 25.66 17.33 3.41 2.30
Bolivia (Plurinational State of) 81.97 23.81 7.50 0.92 0.29
Botswana 9.75 253.83 84.47 3.53 1.17
Brazil 167.92 173.73 47.00 1.53 0.41
Burkina Faso 390.63 33.01 21.50 5.20 3.39
Burundi 250.15 24.92 22.14 9.93 8.82
Cambodia 120.25 17.65 7.05 1.87 0.75
Cameroon 499.15 22.22 13.79 1.93 1.20
Central African Republic 113.76 69.51 70.87 14.71 14.99
Chad 516.30 10.11 3.62 1.14 0.41
China 1752.85 334.60 220.83 5.41 3.57
Comoros 13.03 50.80 42.64 6.12 5.13
Congo 37.44 101.79 44.30 3.23 1.40
Congo, Democratic Republic 1770.31 19.96 14.87 7.34 5.47
Côte d'Ivoire 391.80 26.75 12.21 2.15 0.98
Djibouti 11.01 27.90 9.54 2.63 0.90
Egypt 227.57 65.04 18.85 2.04 0.59
Equatorial Guinea 14.30 353.62 112.66 1.47 0.47
Cost effectiveness of revised WHO guidelines
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counTry ToTal Daly averTeD  
(ThousanDs)
cosT per Daly averTeD (2013 us$) percenTaGe of cosT per Daly 
averTeD in GDp per capiTa (%)
2005  
Guidelines [10]
2013  
Guidelines [8]
2005 
Guidelines
2013 
Guidelines
Eritrea 98.98 45.61 29.62 9.04 5.87
Ethiopia 1568.40 31.57 26.38 6.71 5.61
Gabon 16.33 172.73 46.01 1.51 0.40
Gambia 29.69 28.96 19.11 5.66 3.73
Ghana 352.92 30.57 20.99 1.90 1.31
Guatemala 132.69 44.22 33.12 1.32 0.99
Guinea 224.05 30.11 22.45 5.09 3.80
Guinea–Bissau 41.79 10.65 4.20 1.97 0.78
Haiti 172.73 10.52 5.01 1.36 0.65
India 8522.64 120.40 65.22 8.08 4.38
Indonesia 1137.93 88.40 63.80 2.49 1.79
Iraq 265.05 114.60 58.90 1.78 0.91
Kenya 817.99 16.14 10.00 1.87 1.16
Korea, Democratic People's Republic 82.09 119.29 72.11 23.58 14.25
Kyrgyzstan 24.97 118.16 82.87 10.19 7.15
Lao People's Democratic Republic 124.61 33.64 21.46 2.40 1.53
Lesotho 24.95 20.94 11.31 1.76 0.95
Liberia 64.60 38.45 30.97 9.12 7.34
Madagascar 370.93 34.88 25.61 7.80 5.72
Malawi 215.99 43.60 38.56 16.27 14.39
Mali 515.92 20.83 14.92 3.00 2.15
Mauritania 80.87 34.11 23.72 3.08 2.14
Mexico 212.37 431.59 142.88 4.43 1.47
Morocco 151.78 73.55 43.13 2.53 1.49
Mozambique 423.41 48.62 41.29 8.40 7.13
Myanmar 327.07 78.25 60.48 6.84 5.29
Nepal 165.78 90.43 76.15 12.80 10.78
Niger 635.69 22.63 17.25 5.91 4.51
Nigeria 4499.06 28.45 19.60 1.83 1.26
Pakistan 3212.46 37.42 26.67 2.90 2.07
Papua New Guinea 96.55 54.79 38.86 2.51 1.78
Peru 57.94 220.62 92.82 3.36 1.41
Philippines 595.98 105.66 59.84 4.08 2.31
Rwanda 174.96 34.95 30.11 5.64 4.86
Sao Tome and Principe 2.46 26.25 17.38 1.87 1.24
Senegal 165.98 45.16 30.94 4.38 3.00
Sierra Leone 184.08 17.28 12.65 2.72 1.99
Solomon Islands 4.47 45.92 25.81 3.02 1.70
Somalia 476.59 14.98 10.60 0.20 0.14
South Africa 320.65 156.96 60.73 9.93 3.84
Sudan 772.94 43.67 22.32 1.43 0.73
Swaziland 15.91 36.47 20.27 4.18 2.32
Tajikistan 107.30 51.12 39.35 8.40 6.46
Tanzania, United Republic of 634.76 25.09 18.85 4.37 3.28
Togo 117.10 30.21 22.99 0.67 0.51
Turkmenistan 46.83 91.93 42.53 1.41 0.65
Uganda 654.10 34.33 27.95 6.28 5.11
Uzbekistan 241.88 67.19 46.57 3.91 2.71
Viet Nam 214.59 85.53 35.54 5.36 2.23
Yemen 303.25 74.12 44.68 4.96 2.99
Zambia 311.04 26.27 19.94 1.79 1.36
Zimbabwe 238.01 11.37 6.71 1.44 0.85
Total 39 613.61
Median (IQR) 212.37  
(82.00–493.51)
38.45 
(26.25–87.68)
26.67  
(17.75–46.43)
DALYs – disability adjusted life years, GDP – gross domestic product
Table 4. Continued
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lines will result in slightly higher costs (per patient) at community and first level facility levels due to the 
use of oral amoxicillin (Table 2), the substantial reduction in costs at the hospital level would substantial-
ly decrease the overall economic burden on the health care system in low–income countries (Table 2) and 
save monies. However, the cost savings are comparatively lower in high HIV–burden settings (Table 3).
This study shows the significant financial and social benefits that would accrue and the substantial reduc-
tion in burden on inpatient hospital services that would result from full implementation of the 2013 WHO 
guidelines. The difference in direct medical costs of pneumonia management is mainly due to the reduc-
tion in costs at the hospital level, because most of the pneumonia cases with lower chest in–drawing will 
NOT be admitted but will be treated on an outpatient basis at the first level facility. Implementing the re-
vised guidelines will thus result in reduction in hospitalization that will reduce the burden on already 
overcrowded and poorly resourced hospitals. Fewer beds will be utilized by these (less severely ill) chil-
dren so benefiting more severely ill children (with pneumonia or other severe illness) for whom those 
beds (and consequent care from in–patient hospital staff) will become available. There will also result in 
less pressure on over–stretched inpatient staff, limited resources (such as oxygen which can then be tar-
geted better at children with hypoxaemia), a reduced risk of hospital infections and fewer injection re-
lated serious adverse events. In addition, the reduction in hospitalization rates can be expected to reduce 
non–medical costs and the social and financial burden on families by avoiding family costs associated 
with hospitalisation. Implementing the 2013 WHO guidelines will also make effective treatment with less 
expensive medicines more locally available to families nearer their homes. This will act to reduce trans-
port costs, loss of wages and other opportunity costs.
Although WHO and UNICEF issued joint statements supporting community case management of pneu-
monia, diarrhea (and later malaria) in 2004 [39], CCM as an integrated package was introduced only in 
2012 [40]. Despite there being clear scientific evidence and an established global consensus regarding 
benefits of integrated community services for childhood illnesses, the uptake of CCM has been limited. 
Presently, integrated CCM guidelines are being implemented in only 47 of the 74 Countdown countries 
[25]. The potential savings in the annual recurrent cost by implementing the 2013 WHO guidelines (as 
demonstrated in this paper), could be used to support the costs in starting–up the CCM strategy and/or 
scaling–up the coverage of CCM.
Our estimates have several limitations. First, due to lack of empirical evidence, we have assumed that the 
proportion of children with pneumonia who have tachypnoea and those who have lower chest wall in–
drawing and / danger signs remains same in HIV negative and HIV positive children. This is unlikely to 
be the case, as children with HIV who are not on anti–retroviral therapy, are more likely to develop (very) 
severe disease and die. Preliminary large–scale data from Malawi (high HIV burden with integrated CCM 
implementation) indicates that in program settings, as many as 13% of the children with pneumonia have 
been reported by CHW to have danger signs compared to 2% in our model (Tim Colbourn, personal 
communication). In the model, treatment procedures and cost implications for HIV positive patients with 
chest in–drawing and danger signs are the same in 2005 and 2013 guidelines (Box S1 in Online Supple-
mentary Document). Thus as long as the total percentage of patients with chest in–drawing and danger 
signs remains the same, the proportion of the subgroups does not influence the total management cost. 
While this does not alter the total direct medical costs much in our study, with regards to implementa-
tion of the 2013 IMCI guidelines, this does indicate the need for further research on community–based 
case ascertainment of pneumonia in high HIV burden settings. Moreover, in this study, we estimated the 
cost of childhood pneumonia caused by viruses or bacteria, and did not include complications of pneu-
monia, such as pleural effusion and empyema, lung abscess and pneumothorax. Children presenting 
other conditions with wheeze (such as bronchiolitis and asthma), with stridor (such as viral croup or 
diphtheria) or chronic cough (such as tuberculosis and pertussis) were not included.
Second, we have assumed that in integrated CCM implemented settings, 50% of the rural population 
would be covered by CHWs and the number of CHWs needed per country was obtained by assuming 
one CHW per 1000 rural population. Available data indicate that this may be difficult to achieve. There-
fore, we conducted sensitivity analysis assuming a coverage among rural populations of 9% (when no 
CCM is implemented), and 30% when CCM is fully implemented (Tables S8–10 in Online Supplemen-
tary Document). We also considered a scenario with one CHW per 5000 rural population. We found 
cost savings in all these scenarios (Tables S11–13 in Online Supplementary Document). In the extreme 
scenario with 100% of the rural population were treated by community health workers the results remain 
cost–effective (Tables S2–S4 in Online Supplementary Document).
Cost effectiveness of revised WHO guidelines
www.jogh.org •  doi: 10.7189/jogh.07.010409	 11	 June 2017  •  Vol. 7 No. 1 •  010409
V
IE
W
PO
IN
TS
PA
PE
RS
Acknowledgments: We thank WHO Department of Maternal, Newborn, Child and Adolescent Health for fi-
nancial support for this work. We gratefully acknowledge the personal communication by Tim Colbourn (Uni-
versity College London), Jay Berkley (University of Oxford). The findings and conclusions in this report are 
those of the authors and do not necessarily represent the official views or policies of the WHO.
Severe ALRI Working Group: Harry Campbell, Harish Nair, Ana Lucia Andrade, Cristiana M. Toscano, Shei-
la N. Araujo, Anushua Sinha, Shabir A Madhi. Gulam Khandaker, Jiehui Kevin Yin, Robert Booy, Tanvir M 
Huda, Qazi S Rahman, Shams El Arifeen, Mejbah U. Bhuiyan, Katharine Sturm–Ramirez Angela Gentile, Nor-
berto Giglio, Brad D Gessner, Mardiati Nadjib, Phyllis J Carosone–Link, Eric AF. Simò`es, Jason A Child, Imran 
Ahmed, Zulfi A Bhutta, Sajid B Soofi, Rumana J Khan.
Funding: WHO Department of Maternal, Newborn, Child and Adolescent Health. Shanshan Zhang is sup-
ported by the China Scholarship Council.
Ethics approval and consent to participate: Not applicable.
Authorship declaration: SAQ, HN and HC conceptualised the study. SZ developed the statistical models, con-
ducted data analysis and performed data interpretation. BI conducted data extraction and assisted in data anal-
ysis. HN, HC, SAQ AND KS performed data interpretation. HN and SZ prepared the initial draft of the manu-
script. HC, SAQ, and KS contributed to report writing and critically reviewed the manuscript. All other 
members of the Severe ALRI working Group contributed primary cost data that enabled development of the 
model. All named authors read and approved the final draft of the manuscript.
Competing Interests: SAQ and KS are staff members of the World Health Organization. The authors com-
pleted the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available upon request from 
the corresponding author), and declare no conflict of interest.
Third, we only measured “one–off” direct medical cost from a health care provider’s perspective. Direct 
non–medical costs, such as transportation, over the counter medicines, food for patients and accompa-
nying family members, and other out–of–pocket expenses were not considered in this model. Indirect 
costs (productivity loss and opportunity costs for caregivers) were also not included in this analysis. The 
recurrent costs and program costs of introducing a new policy in a country were not estimated here. These 
costs can often be substantial.
Fourth, we applied a public provider cost profile only. Recent surveillance data in Guatemala, Kenya and 
Thailand found that private physicians treated up to 36% of severe respiratory illness [41]. However, the 
cost information for private care is difficult to obtain and estimate in these countries. By considering only 
a public provider profile our estimated costs are likely to under–estimate true resource needs, especially 
in settings in which private providers are more commonly consulted for treatment of pneumonia.
Fifth, we assumed the same clinical effectiveness for 2005 and 2013 guidelines (ie, they achieved 70% 
mortality reduction). However, there is some debate as to whether the 2013 guidelines can achieve the 
same effectiveness as the previous one [42]. We undertook a sensitivity analysis varying the clinical effec-
tiveness estimate and found that the 2013 guidelines remained cost-effective when the mortality reduc-
tion from pneumonia management for 2013 guideline was only 36% (ie, roughly half that when follow-
ing 2005 guidelines) (Table S16 in Online Supplementary Document).
Our research demonstrates that implementing the WHO 2013 guidelines for pneumonia management is 
not only cost–effective, but can also generate substantial cost–savings for each country (compared to cur-
rent costs implementing 2005 WHO guidelines). Estimation of these avoidable costs is highly relevant 
and should be of great interest to policy makers in developing countries and donor agencies. Our esti-
mates provide a vital piece of evidence from an economic perspective, to encourage policy makers at the 
national level and external funding bodies to make informed decisions in setting priorities and budget 
lines for pneumonia treatment within national programmes. Additionally, the use of scarce resources could 
be maximized toward the development and advancement of integrated CCM where referral is not pos-
sible and improving the quality of care at the primary, secondary and tertiary level health facilities. We 
also postulate that the cost savings are mainly in low HIV settings. Therefore, further research is required 
into more cost-effective treatment strategies for pneumonia in high HIV burden settings, especially where 
there is good coverage with anti–retroviral therapy.
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